Lupin gets USFDA nod for generic drug
- Country:
- India
Drug maker Lupin on Wednesday said it has received approval from the US health regulator to market a generic medication which is used to treat primary biliary cholangitis.
The company has received approval from the US Food and Drug Administration (USFDA) for Obeticholic Acid tablets (5 mg and 10 mg), the Mumbai-based drug maker said in a statement.
The company's product is a generic equivalent of Intercept Pharmaceuticals, Inc's Ocaliva tablets, it added.
The product will be manufactured at the company's Nagpur-based manufacturing facility, Lupin said. As per IQVIA MAT March 2023 sales data, Obeticholic Acid tablets had estimated annual sales of USD 262 million in the US. Shares of Lupin ended 0.11 per cent at Rs 804.55 apiece on the BSE.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Vice president to address valediction ceremony of IRS passing-out batch in Nagpur Monday
All eyes on Nagpur, a former Cong bastion, due to 'development man' Gadkari
Odisha man fleeing to Chhattisgarh after stealing from Gujarat temple held in Nagpur
Man rides two-wheeler sans clothes on Nagpur streets; booked
Nagpur Lok Sabha constituency: BJP's Nitin Gadkari confident of third straight victory, to face Congress' Vikas Thakre on April 19